Goserelin (Zoladex) versus danazol for endometriosis: the North American experience

Damario, Mark A; Rock, John A.

doi:10.1111/j.1471-0528.1994.tb13679.x

Cited by 8 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, some physicians counteract these effects with small amounts of concurrent hormonal supplementation, usually a small amount of estrogen. This is known as "addback" estrogen therapy (Damario and Rock, 1994). The addition of small doses of estrogen, while helpful in relieving symptoms, defeats the purpose of GnRH agonist therapy.…”

Section: Discussionmentioning

confidence: 99%

“…It appears that alterations in bone mass on GnRH agonists are partially to completely reversible within 6 months after discontinuation of therapy. However, the use of GnRH agonists beyond 6 months' duration is not recommended until their safety regarding their effects on bone density can be further evaluated (Damario and Rock, 1994).…”

Section: Side Effects Associated With Gnrh Agonistsmentioning

confidence: 98%

“…Because GnRH agonists have a prolonged half-life and increased potency, ultimately, there is a down-regulation of GnRH receptor numbers resulting in an inhibition of the release of FSH and LH. Within 4 weeks after the initiation of GnRH agonists, plasma concentrations of androgens and estrogens fall to levels seen after oophorectomy or castration (Damario and Rock, 1994). Thus, GnRH agonists are potentially effective in treating disorders that are aggravated either by testosterone or estrogen (Garner, 1994).…”

Section: Introductionmentioning

confidence: 97%

See 2 more Smart Citations

Depressive symptoms associated with gonadotropin-releasing hormone agonists

1998

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Side Effects Associated With Gnrh Agonistsmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Depressive symptoms associated with gonadotropin-releasing hormone agonists

1998

View full text Add to dashboard Cite

“…20,21,44 Damario found persistent decreases in BMD up to 48 weeks after treatment of endometriosis with Zoladex. 39 Many studies, however, have no follow-up with respect to recovery of BMD. 17 Overall, the clinical impression is that Lupron alters bone metabolism through its effect on estrogen secretion although a GnRH-a-induced inhibition of growth hormone, and insulin-like growth factor-I may also contribute to alterations in the calcium metabolism in bones.…”

Section: Gnrh-a Side-effectsmentioning

confidence: 99%

Preserving ovarian function in patients receiving cyclophosphamide

Slater

Liang

McCune

et al. 1999

Lupus

View full text Add to dashboard Cite

“…Oral contraceptives containing two different amounts of oestrogen were used as it has been suggested that their effect depends on the amount of oestrogenic component (Goldzieher, 1989). Danazol was included because it is the hormonal agent most frequently used to treat endometriosis (Barbieri et al, 1982;Dmowski, 1990;Damaria and Rock, 1994).…”

Section: Introductionmentioning

confidence: 99%

Is hormonal treatment efficacious in the management of ovarian cysts in women with histories of endometriosis?

Nezhat

Borhan

et al. 1996

Human Reproduction

View full text Add to dashboard Cite

In a controlled, randomized study, we evaluated the effectiveness of various hormonal regimens in treating 70 women (mean age 34.7 +/- 5.7 years) who had unilateral of bilateral ovarian cysts presumed to be physiological (functional) and a history of endometriosis. The patients were assigned randomly to one of the following groups: group I (control), no treatment; group II, oral contraceptives (35 micrograms ethinyl oestradiol and 1 mg norethindrone); group III, oral contraceptives (50 micrograms ethinyl oestradiol and 1 mg norethindrone); group IV, danazol 800 mg/day. Serum CA-125 concentrations were measured in 32 women. All medications were taken continuously for 6 weeks. Subjects were re-evaluated by pelvic examination and transvaginal ultrasound. Those with persistent cysts were offered diagnostic and possible operative laparoscopy. As 11 patients did not complete the study and five did not follow-up, the final study population comprised 54 women. At 6 weeks follow-up, complete resolution of cysts was found in: group I, 12 out of 18 (66.7%); group II, five out of none (55.6%); group III, eight out of 14 (57.1%); and group IV, seven out of 13 (53.9%). Two of the 22 women with persistent cysts opted for 6 weeks further medical therapy and achieved complete resolution; 19 underwent laparoscopy, and one was lost to follow-up. All laparoscopic findings revealed benign masses. We found no statistically significant effect when hormonal treatment was compared with expectant management. There was no correlation between serum CA-125 concentrations and the persistence of resolution of cysts.

show abstract

Goserelin (Zoladex) versus danazol for endometriosis: the North American experience

Cited by 8 publications

References 40 publications

Depressive symptoms associated with gonadotropin-releasing hormone agonists

Depressive symptoms associated with gonadotropin-releasing hormone agonists

Preserving ovarian function in patients receiving cyclophosphamide

Is hormonal treatment efficacious in the management of ovarian cysts in women with histories of endometriosis?

Contact Info

Product

Resources

About